Last10K.com

Ymabs Therapeutics, Inc. (YMAB) SEC Filing 8-K Material Event for the period ending Friday, June 4, 2021

Ymabs Therapeutics, Inc.

HISTORY TOOLS
CIK: 1722964 Ticker: YMAB

View differences made from one to another to evaluate Ymabs Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ymabs Therapeutics, Inc..

Continue

Assess how Ymabs Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ymabs Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover

Material Contracts, Statements, Certifications & more

Ymabs Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: YMAB
CIK: 1722964
Form Type: 8-K Corporate News
Accession Number: 0001104659-21-076752
Submitted to the SEC: Fri Jun 04 2021 9:14:52 AM EST
Accepted by the SEC: Fri Jun 04 2021
Period: Friday, June 4, 2021
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/ymab/0001104659-21-076752.htm